235 related articles for article (PubMed ID: 10848718)
1. Influence of hydroxychloroquine on the bioavailability of oral metoprolol.
Somer M; Kallio J; Pesonen U; Pyykkö K; Huupponen R; Scheinin M
Br J Clin Pharmacol; 2000 Jun; 49(6):549-54. PubMed ID: 10848718
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Bramer SL; Suri A
Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
Werner U; Werner D; Rau T; Fromm MF; Hinz B; Brune K
Clin Pharmacol Ther; 2003 Aug; 74(2):130-7. PubMed ID: 12891223
[TBL] [Abstract][Full Text] [Related]
6. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
7. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.
Koytchev R; Alken RG; Vlahov V; Kirkov V; Kaneva R; Thyroff-Friesinger U; Rehak E
Eur J Clin Pharmacol; 1998 Aug; 54(6):469-74. PubMed ID: 9776437
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
9. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
Blake CM; Kharasch ED; Schwab M; Nagele P
Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers.
Stoll F; Blank A; Mikus G; Czock D; Weiss J; Meyer-Tönnies MJ; Gümüs KS; Tzvetkov M; Burhenne J; Haefeli WE
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):101-109. PubMed ID: 38114885
[TBL] [Abstract][Full Text] [Related]
12. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
[TBL] [Abstract][Full Text] [Related]
13. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
[TBL] [Abstract][Full Text] [Related]
15. Enhanced oral bioavailability of metoprolol with gallic acid and ellagic acid in male Wistar rats: involvement of CYP2D6 inhibition.
Athukuri BL; Neerati P
Drug Metab Pers Ther; 2016 Dec; 31(4):229-234. PubMed ID: 27875319
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
[TBL] [Abstract][Full Text] [Related]
17. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
Deroubaix X; Lins RL; Lens S; Demblon C; Jeanbaptiste B; Poelaert D; Stockis A
Int J Clin Pharmacol Ther; 1996 Feb; 34(2):61-70. PubMed ID: 8929748
[TBL] [Abstract][Full Text] [Related]
18. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers.
Koch HJ; Hartmann M; Bliesath H; Huber R; Steinijans VW; Mascher H; Wurst W
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):420-3. PubMed ID: 8897078
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.
Taguchi M; Nozawa T; Kameyama T; Inoue H; Takesono C; Mizukami A; Hashimoto Y
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):385-8. PubMed ID: 12915955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
